Evidence map›Paper›PMID 40226477›Full record

ArticleAmerican journal of cancer research2025

Immune cell infiltration as a prognostic factor in endometrial cancer: a meta-analysis.

Yibin Lin, Qiaoming Lin, Qi Guan, Danru Chen, Yan Zhou, Sang Li

Abstract read
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yibin LinDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou 350014, Fujian, PR China.
Qiaoming LinDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou 350014, Fujian, PR China.
Qi GuanDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou 350014, Fujian, PR China.
Danru ChenDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou 350014, Fujian, PR China.
Yan ZhouDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou 350014, Fujian, PR China.
Sang LiDepartment of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou 350014, Fujian, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The immune system's role in cancer development and progression is receiving increasing attention. Endometrial cancer, common gynecological malignancy, has exhibited promising responses to immunotherapies. This study aims to assess the prognostic significance of various immune cell subsets in endometrial cancer, focusing on potential novel biomarkers and therapeutic targets. A systematic literature review and meta-analysis were conducted. Eleven eligible studies, comprising 2,319 patients with endometrial cancer, were included. The primary outcome was the association between levels of immune cell types, particularly CD8+ T cells, and overall prognosis. The meta-analysis found that high levels of tumor-infiltrating lymphocytes (TILs), particularly CD8+ T cells, were significantly associated with better overall prognosis in endometrial cancer patients. These findings suggest that the tumor immune microenvironment plays a crucial role in endometrial cancer prognosis. This meta-analysis indicates that higher levels of CD8+ T cells in the tumor microenvironment are linked to improved prognosis in endometrial cancer, underscoring the immune system's potential in prognostication and therapy.

Indexed as

endometrial cancerImmune cell infiltrationpersonalized treatmentprognostic biomarkerstumor microenvironment

Identifiers

PMID40226477
PMCPMC11982738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.